ORKA vs IMVT vs REGN vs DAWN

For growth investors, Day One Biopharmaceuticals, Inc.

(DAWN) is the stronger pick with 20. 6% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 2x trailing P/E (15. 5x forward), making it the more compelling value choice. Analysts rate Oruka Therapeutics, Inc. (ORKA) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Oruka Therapeutics, Inc.

(ORKA) delivered a total return of +128. 6%, compared to -8. 4% for Day One Biopharmaceuticals, Inc. (DAWN). Over 10 years, the gap is even starker: IMVT returned +190. 9% versus ORKA's -89. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Day One Biopharmaceuticals, Inc.

(DAWN) is the lower-risk stock at 0. 25β versus Oruka Therapeutics, Inc. 's 1. 50β — meaning ORKA is approximately 492% more volatile than DAWN relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Day One Biopharmaceuticals, Inc.

(DAWN) is pulling ahead at 20. 6% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Oruka Therapeutics, Inc. grew EPS 39. 7% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -67. 8% for Day One Biopharmaceuticals, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -80. 8% for DAWN. At the gross margin level — before operating expenses — DAWN leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ORKA: 111.

1% to $136. 38.

In this comparison, REGN (0.

5% yield) pays a dividend. ORKA, IMVT, DAWN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Day One Biopharmaceuticals, Inc.

(DAWN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25)). Oruka Therapeutics, Inc. (ORKA) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DAWN: -8. 4%, ORKA: -89. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ORKA is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; REGN is a mid-cap deep-value stock; DAWN is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.